Semaglutide at a dose of 2.4 mg weekly is the first weekly long-acting GLP-1 RA approved for non-syndromic obesity treatment with a mean weight change of 14.9% in individuals with obesity without diabetes (39) and 9.6% in individuals with obesity and concomitant diabetes (40). The gene discussed is GLP1R; the disease is obesity disorder.